<code id='69C4466A29'></code><style id='69C4466A29'></style>
    • <acronym id='69C4466A29'></acronym>
      <center id='69C4466A29'><center id='69C4466A29'><tfoot id='69C4466A29'></tfoot></center><abbr id='69C4466A29'><dir id='69C4466A29'><tfoot id='69C4466A29'></tfoot><noframes id='69C4466A29'>

    • <optgroup id='69C4466A29'><strike id='69C4466A29'><sup id='69C4466A29'></sup></strike><code id='69C4466A29'></code></optgroup>
        1. <b id='69C4466A29'><label id='69C4466A29'><select id='69C4466A29'><dt id='69C4466A29'><span id='69C4466A29'></span></dt></select></label></b><u id='69C4466A29'></u>
          <i id='69C4466A29'><strike id='69C4466A29'><tt id='69C4466A29'><pre id='69C4466A29'></pre></tt></strike></i>

          Home / comprehensive / entertainment

          entertainment


          entertainment

          author:focus    Page View:527
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In